The oral biologics revolution: How macrocyclic peptides could reshape drug delivery

Pallavi Madhiraju- June 12, 2025 0

Macrocyclic peptides are revolutionizing oral biologics. Explore how Merck, Protagonist, and others are turning injectables into convenient, high-impact pills. Read More

Can IonQ become the Nvidia of quantum computing? What the Oxford Ionics deal signals about platform consolidation

Pallavi Madhiraju- June 10, 2025 0

IonQ’s deal to acquire Oxford Ionics marks a strategic shift toward becoming the “Nvidia of quantum.” Explore what this means for quantum computing’s future. Read More

Quantum leap: IonQ targets Oxford Ionics in $1bn+ deal to hit 2 million qubits by 2030

Pallavi Madhiraju- June 9, 2025 0

IonQ’s $1.075B acquisition of Oxford Ionics boosts its bid for fault-tolerant quantum systems by 2030. Find out what this means for the industry. Read More

How AI is transforming cancer diagnosis and treatment planning in 2025

Pallavi Madhiraju- June 6, 2025 0

AI is reshaping cancer care—improving diagnosis, guiding treatment, and boosting efficiency across hospitals. Discover how it's redefining oncology workflows in 2025. Read More

Checkpoint inhibitors in early-stage cancer: A new era of adjuvant therapy is taking shape

Pallavi Madhiraju- June 4, 2025 0

Checkpoint inhibitors are redefining early-stage cancer care. Find out how Tecentriq, Keytruda, and others are competing for the adjuvant immunotherapy market. Read More

Racing to save lives: Indy 500 and NASCAR drivers unite to fight prostate cancer in veterans

Pallavi Madhiraju- May 24, 2025 0

Find out how ZERO Prostate Cancer and racing legends are spotlighting veterans’ health at Indy 500 and NASCAR this Memorial Day weekend. Read More

AstraZeneca’s $13.6bn Q1 2025 sales surge as cancer drugs and AI deals set stage for $80bn goal

Pallavi Madhiraju- April 30, 2025 0

Explore how AstraZeneca’s strong Q1 2025 results, new drug approvals, and AI-powered R&D are reshaping its global growth story. Read More

Imfinzi gains EU approval in resectable NSCLC, bolstering AstraZeneca’s oncology pipeline

Pallavi Madhiraju- April 4, 2025 0

AstraZeneca’s Imfinzi-based regimen approved in the EU to cut lung cancer recurrence by 32%—learn how this could redefine early-stage NSCLC treatment. Read More

EU approves Enhertu as first HER2-targeted therapy for HR-positive, HER2-low metastatic breast cancer

Pallavi Madhiraju- April 4, 2025 0

Discover how Enhertu’s EU approval is transforming care for HR-positive, HER2-low and HER2-ultralow breast cancer, and what it means for AstraZeneca’s future. Read More

AstraZeneca to invest $2.5bn in Beijing R&D hub, biotech partnerships, and vaccine manufacturing

Pallavi Madhiraju- March 25, 2025 0

AstraZeneca is investing $2.5 billion in Beijing for R&D, biotech partnerships, and vaccine production. Learn how this move impacts its market strategy. Read More